Replies to post #372083 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

Thanks. Nothing new about the trial in the article. From that article, here are some quotes.

* An interim analysis of the intent-to-treat population in a phase III DCVax-L study demonstrated a median overall survival of 23.1 months from the surgery and a median overall survival of patients with methylated MGMT of 34.7 months from surgery; both represent a significant increase when compared with that of standard of care treatment.

* The benefits derived from therapeutic vaccines are often observed at later time points after treatment when compared with other therapy types. This factor is often demonstrated in the tail of survival curves.

[EMHLondonUK]

Well done Nick. Appreciate the resourcefulness.

[sentiment_stocks]

Thank you Nick! Read the entire thing. It offers a very helpful overview of vaccines and how they have been used in the treatment of brain cancers, including GBM. Too bad the unblinded data for the DCVax-L trial wasn’t available for publication before this book was published. Again, thanks for sharing this PDF with us.

[Lykiri]

Nick119, thank you for sharing the pdf for the (or one of) portion of the book that deal with DCvax.